Marinus Pharma
Dedicated to the development of innovative therapeutics to treat seizure disorders
United States
111 employees
Post-IPO Equity
Biopharma, Biotechnology +3
General Information
United States
BounceWatch is an independent company data service, not affiliated with Marinus Pharma. To contact Marinus Pharma, visit marinuspharma.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
United States Market
Biopharma
About Marinus Pharma
Taxonomy: pharmaceuticals, therapeutics, seizure disorders, ganaxolone, clinical-stage biopharmaceutical, neurology, pediatric care, acute care, chronic care, drug development, innovation
Funding Rounds & Investors (10)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Debt | Undisclosed | - |
|
31 Oct 2022 |
| Post IPO Equity | Undisclosed | - |
|
04 Apr 2022 |
| Post IPO Debt | Undisclosed | - |
|
17 May 2021 |
| Post IPO Equity | Undisclosed | - |
|
29 May 2020 |
| Post IPO Equity | Undisclosed | - |
|
10 Dec 2019 |
| Post IPO Equity | Undisclosed | - |
|
11 Dec 2018 |
| Post IPO Equity | Undisclosed | - |
|
14 Sep 2017 |
| Venture Series Unknown | Undisclosed | - |
|
19 Dec 2012 |
| Series B | Undisclosed | - |
|
03 May 2009 |
| Series A | Undisclosed | - |
|
25 Oct 2005 |
Marinus Pharma Alternatives & Competitors
Autifony are dedicated to developing new medicines to treat rare genetic CNS disorders
DEVELOPING INNOVATIVE TREATMENTS FOR GENITOURINARY TRACT DISORDERS
Clinical-stage biotechnology company dedicated to discovery and development of therapeutics in infec...
FAQ About Marinus Pharma
Source: BounceWatch company record for Marinus Pharma, https://bouncewatch.com/company/marinus-pharma, updated 7 January 2025. When citing, please name BounceWatch and link this page.
